NASDAQ$GOCO
GoHealth Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
GoHealth reported a Q3 net loss of $165.85 million on revenues of $34.19 million amid a strategic pullback in Medicare Advantage volume.
GoHealth’s Q3 2025 results reflect an intentional shift away from volume-driven growth to focus on retention, quality, and strategic flexibility. While revenue dropped significantly year-over-year, the company reinforced its core capabilities to align with changing market dynamics.
- Net revenue for Q3 2025 declined to $34.19 million from $118.29 million in Q3 2024.
- The company posted a net loss of $165.85 million, primarily due to impairment charges and higher G&A expenses.
- Submissions dropped 57% YoY to 72,183, reflecting the company’s strategic pullback.
- Adjusted EBITDA was $(47.09) million with a margin of -137.7%.
Headline financials
Revenue & EPS history
GoHealth · Revenue · Quarterly
$34.2M
Revenue by segment
GoHealth · $11.9M total across 4 segments · Q1 2026
- Medicare Agency Revenue$9.8M—82.2%
- Other Non-Agency Revenue$1.76M—14.8%
- Medicare Non-Agency Revenue$200K—1.7%
- Other Agency Revenue$155K—1.3%
Forward guidance
GoHealth expects continued pressure on top-line growth due to its deliberate pullback, but believes its strategic positioning and retained core capabilities will enable it to capitalize when the market stabilizes.
Tailwinds
- Preserved liquidity with $32.08M in cash and equivalents.
- Strengthened retention model and platform efficiency.
- Maintained leadership position in Special Needs Plans.
- Improved focus on high-quality member base over raw growth.
- Streamlined cost structure to enhance operational flexibility.
Headwinds
- 71% YoY revenue decline highlights impact of reduced volume.
- Massive impairment charge of $206M affected profitability.
- Submissions fell 57% YoY to 72,183 in Q3 2025.
- Adjusted EBITDA margin deeply negative at -137.7%.
- Sales per submission decreased 34% YoY to $461.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2025
-7.7%
Avg return
Earnings day
-9.0%
Avg return
5 days after
-6.6%
Avg return
30 days after
26%
6 / 23 earnings
Positive
+32.2%
Q1 2023
Best reaction
-45.5%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.5% | — | — | |
| Q3 2025 | -24.4% | -32.0% | -12.8% | |
| Q2 2025 | -9.0% | -7.6% | -23.8% | |
| Q1 2025 | -0.6% | -17.4% | -21.4% | |
| Q4 2024 | -14.4% | -14.9% | -32.8% | |
| Q3 2024 | -6.6% | -0.4% | -15.4% | |
| Q2 2024 | -21.4% | -28.3% | -34.0% | |
| Q1 2024 | -8.0% | -11.1% | +2.2% | |
| Q4 2023 | -13.0% | -25.7% | -27.0% | |
| Q3 2023 | +2.3% | +6.7% | +7.4% | |
| Q2 2023 | +6.8% | +6.3% | -17.2% | |
| Q1 2023 | +32.2% | +44.8% | +99.5% | |
| Q4 2022 | -19.9% | -6.2% | -18.5% | |
| Q3 2022 | -16.7% | -9.4% | +95.3% | |
| Q2 2022 | -31.5% | -43.3% | -57.0% | |
| Q1 2022 | +11.1% | +4.9% | +6.5% | |
| Q4 2021 | +23.7% | +37.7% | -9.8% | |
| Q3 2021 | +1.1% | -4.7% | -18.1% | |
| Q2 2021 | -45.5% | -42.2% | -34.7% | |
| Q1 2021 | -2.7% | -5.6% | -4.0% | |
| Q4 2020 | -14.9% | -16.9% | -4.1% | |
| Q3 2020 | -14.9% | -15.1% | +1.8% | |
| Q2 2020 | -10.5% | -18.5% | -27.1% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro